| Dr Shannon Dianne Puckett May, PHARMD | |
|
123 S 27th St, Billings, MT 59101-4227 | |
| (406) 247-3350 | |
| (406) 247-3389 |
| Full Name | Dr Shannon Dianne Puckett May |
|---|---|
| Gender | Female |
| Speciality | Pharmacist - Pharmacist Clinician (phc)/ Clinical Pharmacy Specialist |
| Location | 123 S 27th St, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154667079 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Shannon Dianne Puckett May, PHARMD 2713 Stinson Pl, Billings, MT 59102-1344 Ph: (406) 459-6559 | Dr Shannon Dianne Puckett May, PHARMD 123 S 27th St, Billings, MT 59101-4227 Ph: (406) 247-3350 |
News Archive
Merck, known as MSD outside the United States and Canada, and Astellas US LLC, the U.S. subsidiary of Astellas Pharma Inc. today announced that they have entered into an agreement under which Merck, through a subsidiary, will acquire the exclusive rights to develop and commercialize the investigational intravenous formulation of vernakalant (vernakalant i.v.) in Canada, Mexico and the United States from Astellas.
The Pharmaceutical Care Management Association (PCMA) released the following statement today on new legislation introduced by Congressman Stephen F. Lynch (D-Mass.) — the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act (H.R. 4489) — which would increase prescription drug costs and reduce choices for federal employees
MindFrame Inc. today announces the establishment of an ischemic stroke Registry that will collect real-world clinical and procedural data through a secure web-based portal accessible only to registered clinician members.
Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.
Patient Safety Technologies, Inc. announced today the closing of a $6.0 million private placement financing. The new capital will primarily be used to fund working capital and the continued growth of the Company.
› Verified 2 days ago
Hannah Elizabeth Johnson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1649 Main St, Billings, MT 59105 Phone: 406-254-2842 | |
David Sanks, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2525 King Ave W, Billings, MT 59102 Phone: 406-652-9688 | |
Joshua Teynor, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1602 Main St, Billings, MT 59105 Phone: 406-245-0178 | |
Gerald Robbin Fisher, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3333 Grand Ave, Billings, MT 59102 Phone: 406-652-1620 | |
Dr. Natalie Marie Waterfall, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 670 Main St, Billings, MT 59105 Phone: 406-245-6979 | |
Barbara Metzger, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2290 King Ave W, Billings, MT 59102 Phone: 406-656-8556 | |
Kailey Klinger, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1775 Spring Creek Lane, Billings, MT 59102 Phone: 406-373-3500 Fax: 406-373-3607 |